Abstract is: Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis. Ranibizumab (Lucentis) was approved for medical use in the United States in June 2006. Ranibizumab (Susvimo) was approved for medical use in the United States in October 2021.
| P267 | ATC code | S01LA04 |
| P231 | CAS Registry Number | 347396-82-1 |
| P592 | ChEMBL ID | CHEMBL1201825 |
| P9272 | DeCS ID | 55979 |
| P715 | DrugBank ID | DB01270 |
| P9635 | electronic Essential Medicines List medicine ID | 513 |
| P646 | Freebase ID | /m/0fv_4x |
| P595 | Guide to Pharmacology Ligand ID | 6779 |
| P665 | KEGG ID | D05697 |
| P10245 | MedlinePlus drug identifier | a607044 |
| P486 | MeSH descriptor ID | D000069579 |
| P672 | MeSH tree code | D12.776.124.486.485.114.224.060.868 |
| D12.776.124.790.651.114.224.060.868 | ||
| D12.776.377.715.548.114.224.200.868 | ||
| P6366 | Microsoft Academic ID | 2781100027 |
| P2115 | NDF-RT ID | N0000171789 |
| P10283 | OpenAlex ID | C2781100027 |
| P3345 | RxNorm ID | 595060 |
| P4527 | UK Parliament thesaurus ID | 441726 |
| P2892 | UMLS CUI | C1566537 |
| P652 | UNII | ZL1R02VT79 |
| P11143 | WikiProjectMed ID | Ranibizumab |
| P3350 | World Health Organisation international non-proprietary name numeric ID | 8313 |
| P3780 | active ingredient in | Lucentis | Q29006144 |
| P1552 | has characteristic | biopharmaceutical | Q679692 |
| P527 | has part(s) | carbon | Q623 |
| P366 | has use | medication | Q12140 |
| P3493 | legal status (medicine) | boxed warning | Q879952 |
| P2175 | medical condition treated | glaucoma | Q159701 |
| retinal disease | Q550455 | ||
| diabetic retinopathy | Q631361 | ||
| eye disease | Q3041498 | ||
| Kuhnt-Junius degeneration | Q18553965 | ||
| retinal vein occlusion | Q18554884 | ||
| cystoid macular edema | Q18556331 | ||
| exudative vitreoretinopathy 1 | Q55345659 | ||
| macular retinal edema | Q1813737 | ||
| P3489 | pregnancy category | US pregnancy category C | Q28123617 |
| P636 | route of administration | intravitreal administration | Q180609 |
| P2868 | subject has role | monoclonal antibody | Q422248 |
| angiogenesis inhibitor | Q574834 | ||
| P2275 | World Health Organisation international non-proprietary name | ranibizumab |
| Q18553965 | Kuhnt-Junius degeneration |
| Q1266519 | corneal neovascularization |
| Q18556331 | cystoid macular edema |
| Q631361 | diabetic retinopathy |
| Q55345659 | exudative vitreoretinopathy 1 |
| Q3041498 | eye disease |
| Q159701 | glaucoma |
| Q1813737 | macular retinal edema |
| Q550455 | retinal disease |
| Q18554884 | retinal vein occlusion |
| Q63830171 | 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) |
| Q66082794 | 24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME. |
| Q64395847 | 25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial |
| Q67133642 | 25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China |
| Q66075132 | 30g vs 33g Needle for Intravitreal Injections |
| Q64045437 | A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study |
| Q64601667 | A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients |
| Q64672313 | A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD) |
| Q64397716 | A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer) |
| Q64792224 | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) |
| Q87077305 | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (2018-10-01) |
| Q63338390 | A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema |
| Q61894429 | A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients |
| Q64789193 | A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD |
| Q113889283 | A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the |
| Q113912196 | A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections |
| Q65353790 | A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy. |
| Q61969788 | A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema |
| Q64354547 | A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy |
| Q86166387 | A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy (2013-08-31) |
| Q66395018 | A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab |
| Q63811665 | A Phase III Study to Evaluate the Port Delivery System Implant With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway) |
| Q63831753 | A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study) |
| Q67127485 | A Proof-of-Concept Study of RO6867461 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) |
| Q64709616 | A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD |
| Q113944838 | A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy |
| Q65470409 | A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO |
| Q63315739 | A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macula |
| Q65346608 | A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration |
| Q65376495 | A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration |
| Q64613296 | A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema |
| Q64651601 | A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion |
| Q106642569 | A Study Of The Efficacy And Safety Of The Port Delivery System With Ranibizumab In Patients With Neovascular Age-Related Macular Degeneration Previously Treated With Intravitreal Agents Other Than Ranibizumab |
| Q113910245 | A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration |
| Q65386220 | A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration |
| Q65392585 | A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS) |
| Q64608842 | A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration |
| Q64608053 | A Study of Abicipar Pegol in Patients With Diabetic Macular Edema |
| Q64608841 | A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration |
| Q65471258 | A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD |
| Q64683944 | A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial) |
| Q65400615 | A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema |
| Q64677960 | A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR) |
| Q65383214 | A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE) |
| Q65383222 | A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE) |
| Q61920719 | A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration |
| Q66032806 | A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) |
| Q64349087 | A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. |
| Q61918462 | A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO) |
| Q61918477 | A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE) |
| Q113896117 | A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) |
| Q64599975 | A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema |
| Q66044340 | A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD) |
| Q66036160 | A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration |
| Q64395224 | A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) |
| Q64598972 | A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) |
| Q65541356 | A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) |
| Q63399653 | A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME) |
| Q66037023 | A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration |
| Q113943399 | A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD |
| Q113925868 | A Study to Investigate RO7200220 in Combination With Ranibizumab in Diabetic Macular Edema |
| Q113925867 | A Study to Investigate RO7200220 in Diabetic Macular Edema |
| Q64041125 | ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration |
| Q64613790 | Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide |
| Q65355538 | Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration |
| Q65465363 | Aflibercept in Recurrent or Persistent CNV |
| Q63322224 | An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2) |
| Q65388295 | An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO |
| Q61932733 | An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD |
| Q64217028 | An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Relate |
| Q64622432 | An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. |
| Q64222979 | Analysis of Aqueous and Vitreous Humor |
| Q66046559 | Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis |
| Q61955366 | Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration |
| Q76981899 | Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery |
| Q66062796 | Anti-VEGF Therapy Versus Dexamethasone Implant for DME |
| Q113927064 | Anti-VEGF in Real-world |
| Q63335522 | Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy |
| Q65367252 | Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization. |
| Q64789149 | Assessment of Color Vision in Diabetic Patients |
| Q65379458 | Bevacizumab Versus Ranibizumab for Diabetic Retinopathy |
| Q64648846 | Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema |
| Q64659416 | Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration |
| Q63320620 | Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion |
| Q63839152 | Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye |
| Q105493066 | Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation |
| Q66410035 | CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab |
| Q65470310 | CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography |
| Q64612217 | Canadian Treat and Extend Analysis Trial With Ranibizumab |
| Q67133474 | Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema |
| Q65380441 | Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration |
| Q63812271 | Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema |
| Q63807159 | Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab |
| Q113929261 | Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema |
| Q64221785 | Cohort Study of the Clinical Course of Macular Diseases in Japanese |
| Q65353892 | Cohort Study of the Clinical Course of Macular Diseases in Kagawa |
| Q64719713 | Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment |
| Q65398368 | Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema |
| Q64708713 | Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration |
| Q61894330 | Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema |
| Q66072538 | Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO |
| Q62054120 | Combination of Intravitreal Ranibizumab With or Without Micropulse Diode Laser for the Treatment of DME |
| Q64664510 | Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration |
| Q64335708 | Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema |
| Q64048416 | Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks |
| Q63592416 | Combined Ranibizumab and Iluvien for Diabetic Macular Oedema |
| Q64046643 | Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study |
| Q64644123 | Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema |
| Q64673764 | Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization |
| Q64606496 | Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME |
| Q113920268 | Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
| Q65359219 | Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity |
| Q64600948 | Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen |
| Q64642985 | Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME) |
| Q64642983 | Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO) |
| Q63584843 | Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD |
| Q74282790 | Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME) |
| Q64724903 | Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial |
| Q64070476 | Comparison of Changes of Inflammatory Proteins in Aqueous Humour of Subjects Treated With Avastin vs Lucentis |
| Q64662098 | Comparison of Intravitreal Ranibizumab and Macular Grid-pattern Laser for Treatment of Diabetic Macular Edema |
| Q64652944 | Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO) |
| Q66396639 | Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose |
| Q64802067 | Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen |
| Q64613704 | Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients |
| Q63833703 | Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration |
| Q63830219 | Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) |
| Q61975174 | Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Primarily Intra-retinal Fluid) Treatment. |
| Q61894674 | Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept |
| Q65363984 | Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE) |
| Q65395362 | Cytokeratin 8 Level in Age-related Macular Degeneration |
| Q66072328 | Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab |
| Q64725107 | Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab |
| Q65354576 | Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion |
| Q65346112 | Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema |
| Q113893859 | Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only. |
| Q113921189 | Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome |
| Q63834497 | Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration |
| Q66074425 | Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization |
| Q63320811 | Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema |
| Q66404109 | Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy |
| Q64709822 | ERG/EOG Study in AMD Patients Treated With Ranibizumab |
| Q65365003 | ESBA1008 Microvolume Study |
| Q63336640 | ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients |
| Q63588099 | ETDRS PRP With IVR Versus Retinal Photocoagulation Targeted to Ischemic Retina With IVR for the Treatment of PDR |
| Q65470935 | EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) |
| Q65373791 | Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter |
| Q64665639 | Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO) |
| Q64716757 | Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma |
| Q61909182 | Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema |
| Q61920544 | Effect of Ranibizumab on Malignant Conjunctival Neoplasia |
| Q65337887 | Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration |
| Q94486324 | Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema |
| Q64719483 | Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV) |
| Q66397364 | Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study |
| Q63319555 | Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) |
| Q65474490 | Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema |
| Q65362792 | Efficacy Study of Lucentis in the Treatment of Retinoblastoma |
| Q65368411 | Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration. |
| Q64725837 | Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD |
| Q66547064 | Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD |
| Q64648686 | Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD |
| Q63829477 | Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion |
| Q65357572 | Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema. |
| Q64349228 | Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase |
| Q64676126 | Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema |
| Q64661637 | Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema |
| Q63834747 | Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) |
| Q64622130 | Efficacy and Safety of Ranibizumab 0.5 vs Veteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia |
| Q64649410 | Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) |
| Q64649406 | Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) |
| Q63844242 | Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion |
| Q63812529 | Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion |
| Q65539198 | Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) |
| Q63818199 | Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia |
| Q63831160 | Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus |
| Q63831946 | Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia |
| Q64637015 | Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration |
| Q64047073 | Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy |
| Q67129929 | Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration |
| Q63229053 | Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF |
| Q66079620 | Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration |
| Q64353410 | Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD |
| Q66408067 | Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema |
| Q64696996 | Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration |
| Q65472604 | Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization |
| Q66390163 | Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging |
| Q63571456 | Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD |
| Q64173291 | Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD) |
| Q63835485 | Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration |
| Q66346103 | Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy |
| Q65372100 | Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis |
| Q65472050 | Evaluation of Dosing Interval of Higher Doses of Ranibizumab |
| Q63576580 | Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME |
| Q64621385 | Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration |
| Q65469654 | Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy |
| Q87931784 | Evaluation of Retinal and Vascular Features in Coats Disease After Intravitreal Injections of Ranibizumab |
| Q93475704 | Evaluation of Retinal and Vascular Features in Radiation Maculopathy After Intravitreal Injections of Ranibizumab |
| Q64694196 | Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients |
| Q63334437 | Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes |
| Q65338542 | Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas |
| Q63818055 | Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy |
| Q63597367 | Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD |
| Q67133627 | Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration |
| Q65345024 | Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion |
| Q65353804 | Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD. |
| Q64651507 | Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion |
| Q62054751 | Extension Study for the Port Delivery System With Ranibizumab (Portal) |
| Q66031597 | Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD) |
| Q64644620 | Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO |
| Q62042206 | Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion |
| Q61957646 | FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration |
| Q63831511 | French Evaluation Group Avastin Versus Lucentis |
| Q61894615 | Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing |
| Q66398192 | Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration |
| Q64598852 | Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept |
| Q64642862 | Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD) |
| Q63818891 | Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD |
| Q65347551 | Geographic Atrophy and Intravitreal Ranibizumab Injections |
| Q65316701 | Head to Head Study of Anti-VEGF Treatment. |
| Q61967829 | Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion |
| Q64653021 | HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration |
| Q63336353 | High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy |
| Q63573559 | High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration |
| Q64652646 | High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia |
| Q63811868 | IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab |
| Q64666324 | INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD |
| Q64645832 | IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD |
| Q65385607 | Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration |
| Q65384871 | Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB) |
| Q65365861 | Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD) |
| Q64666471 | Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion |
| Q64626303 | Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab |
| Q65465663 | Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab |
| Q66080504 | Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection |
| Q65384967 | Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation |
| Q65384955 | Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation |
| Q113887788 | Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO) |
| Q65349160 | Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study |
| Q64719412 | Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema |
| Q66394106 | Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy |
| Q64604593 | Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD |
| Q65345718 | Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent |
| Q61922271 | Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab |
| Q64597951 | Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab |
| Q61969141 | Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections |
| Q66409169 | Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis |
| Q66071871 | Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab |
| Q64802092 | Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. |
| Q66395446 | Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy |
| Q65370192 | Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment |
| Q66037025 | Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD) |
| Q66080691 | Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study |
| Q63595452 | Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy |
| Q61955531 | Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab |
| Q65370960 | Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy |
| Q64661107 | Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study) |
| Q66407891 | Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma |
| Q65385616 | Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema |
| Q65385593 | Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy |
| Q113940898 | Intravitreal Ranibizumab Versus Its Combination With Dexamethasone in The Treatment of Diabetic Macular Edema |
| Q66400038 | Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy |
| Q64693195 | Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N) |
| Q65380241 | Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy |
| Q64664521 | Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome |
| Q66387175 | Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion |
| Q113892095 | Intravitreal Ranibizumab in Recurrent ROP |
| Q64663136 | Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments |
| Q66061738 | Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema |
| Q64048146 | Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II) |
| Q64123542 | Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD |
| Q64622122 | Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma |
| Q64708736 | Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis |
| Q65362029 | Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) |
| Q63319973 | Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration |
| Q65349644 | LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration |
| Q63837225 | LUCAS (Lucentis Compared to Avastin Study) |
| Q63592425 | Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema |
| Q61924722 | Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema |
| Q61924668 | Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy |
| Q97045854 | Long-term Need of Ranibizumab Injections With or Without Early Targeted Peripheral Laser Photocoagulation for Treatment of Macular Edema Due to Central Retinal Vein Occlusion |
| Q64349163 | Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion |
| Q65387384 | Lucentis (Ranibizumab) for Eales' Disease |
| Q63817329 | Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation |
| Q63316835 | Lucentis KAV Study |
| Q61921708 | Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration |
| Q64722023 | Lucentis Versus Mitomycin C During Glaucoma Surgery |
| Q64719758 | Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma |
| Q64725226 | Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments |
| Q65473223 | Lucentis for Central Retinal Vein Occlusion (CRVO) |
| Q65381340 | Lucentis for Inflammatory Macular Edema Trial |
| Q63838317 | Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion |
| Q64718585 | Lucentis for New Onset Neovascular Glaucoma |
| Q65383736 | Lucentis for Treatment of Macular Edema |
| Q64677196 | Lucentis in Advanced Macular Degeneration |
| Q64693828 | Lucentis to Treat Pigment Epithelial Detachment |
| Q65355414 | Lucentis to Treat Retinopathy of Prematurity (ROP) 3 Plus Disease |
| Q63832793 | MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2) |
| Q67125292 | Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial |
| Q65536108 | Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT) |
| Q66067050 | Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery |
| Q64040960 | Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration |
| Q113931446 | Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse |
| Q64678739 | Microperimetry and Optical Coherence Tomography (OCT) With Lucentis for Diabetic Macular Edema (DME) |
| Q64220751 | Monocentric Retrospective Observational Study on Patients With Macular Degeneration |
| Q63843171 | Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) |
| Q63400679 | Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR) |
| Q63572263 | Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema |
| Q79111018 | New Concepts in Diabetic Macular Edema (DME) |
| Q67134510 | Noctura400 Treatment for Diabetic Retinopathy (CANDLE) |
| Q105493130 | OCTA and Polypoidal Choroidal Vasculopathy |
| Q113917572 | OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) |
| Q63340078 | OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab |
| Q64610583 | Observation of Treatment Patterns With Lucentis in Approved Indications |
| Q107169667 | Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications |
| Q64354787 | Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients. |
| Q66386849 | Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting |
| Q74286000 | Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy |
| Q89507556 | Outcomes of Subthreshold Laser Versus Intravitreal Injection of Ranibizumab in Diabetic Macular Edema |
| Q65369332 | Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion |
| Q66347333 | Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion |
| Q64351576 | PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy |
| Q63321616 | PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME) |
| Q61935849 | Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy |
| Q64611898 | Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab |
| Q64350181 | Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD |
| Q64716549 | Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration |
| Q106965962 | Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD |
| Q64354463 | Phase II Combination Steroid and Anti-VEGF for Persistent DME |
| Q64719131 | Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study). |
| Q76982778 | Photobiomodulation for the Treatment of Diabetic Macular Edema |
| Q65469827 | Photodynamic and Pharmacologic Treatment of CNV |
| Q64718596 | Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD) |
| Q65469572 | Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration |
| Q64694151 | Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema |
| Q64335568 | Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration |
| Q64643158 | Pilot Study of X-82 in Patients With Wet AMD |
| Q113925195 | Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD |
| Q65377384 | Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations |
| Q113887343 | Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema |
| Q64220606 | Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO |
| Q66407112 | Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study |
| Q64683911 | Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage: |
| Q65379890 | Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab |
| Q67133814 | Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion |
| Q63321130 | Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy |
| Q61975528 | Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT |
| Q64598843 | Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration |
| Q65357631 | Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration |
| Q65389111 | Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study) |
| Q65375603 | Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferat |
| Q64354862 | Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With |
| Q65347067 | RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity |
| Q63815632 | REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study |
| Q99081276 | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
| Q66409340 | Rainbow Extension Study |
| Q64354221 | Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD |
| Q63338884 | Ranibizumab "Treat and Extend" in Diabetic Macular Edma |
| Q65473113 | Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions |
| Q64184521 | Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy |
| Q63339528 | Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab |
| Q64693013 | Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions |
| Q65365771 | Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab |
| Q64621652 | Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study |
| Q64719301 | Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth |
| Q64719263 | Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth |
| Q62109998 | Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome |
| Q64352898 | Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) |
| Q64352900 | Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) |
| Q64646418 | Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion |
| Q64836599 | Ranibizumab Plus Indomethacin |
| Q63816168 | Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD |
| Q64693857 | Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease |
| Q64659259 | Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks |
| Q65379548 | Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy |
| Q65355280 | Ranibizumab Treatment for Age-Related Macular Degeneretion |
| Q67127738 | Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion |
| Q61975500 | Ranibizumab Treatment for Retinal Vein Occlusion |
| Q63817872 | Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment |
| Q113943810 | Ranibizumab Versus Aflibercept for CRVO in Young Patients. |
| Q64804817 | Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema |
| Q65376563 | Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy |
| Q65379286 | Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis |
| Q64645085 | Ranibizumab and Bevacizumab for Diabetic Macular Edema |
| Q64696871 | Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion |
| Q65381554 | Ranibizumab and Reduced Fluence PDT for AMD |
| Q63337058 | Ranibizumab and the Risk of Arterial Thromboembolic Events |
| Q63818797 | Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2) |
| Q63818537 | Ranibizumab as a Rescue Therapy for Diabetic Macular Edema |
| Q65379457 | Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES) |
| Q64655189 | Ranibizumab for Diabetic Traction Retinal Detachment |
| Q61938031 | Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study |
| Q65338162 | Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study |
| Q65369722 | Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision |
| Q63815804 | Ranibizumab for Myopic Neovascularization |
| Q64723143 | Ranibizumab for Neovascularization in Sickle Cell Retinopathy |
| Q64719545 | Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 |
| Q61921577 | Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) |
| Q61975176 | Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept. |
| Q64716888 | Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments |
| Q64725078 | Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging |
| Q64716128 | Ranibizumab for the Inhibition of Neovascularization in Pterygia |
| Q64716102 | Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery |
| Q63806776 | Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) |
| Q64659414 | Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen |
| Q64716620 | Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma |
| Q63813796 | Ranibizumab in Diabetic Vitrectomy |
| Q61934729 | Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial |
| Q65388612 | Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial |
| Q63838577 | Ranibizumab in Patients With Branch Retinal Vein Occlusion |
| Q61914546 | Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery |
| Q63321316 | Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy |
| Q61979152 | Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE) |
| Q61980060 | Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial) |
| Q74282122 | Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema |
| Q65353896 | Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD |
| Q65383179 | Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration |
| Q61917901 | Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) |
| Q61975509 | Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia |
| Q64790054 | Refractive Error and Biometry in Retinopathy of Prematurity |
| Q64604242 | Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration |
| Q113941322 | Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity |
| Q63815811 | Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs |
| Q63813974 | Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion (CRVO) |
| Q64336343 | Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema |
| Q63335464 | Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab |
| Q65336305 | Retinal Sensitivity in BRVO After Anti-VEGF Therapy |
| Q64673660 | Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD) |
| Q63394108 | Retrospective Review of Proliferative Diabetic Retinopathy Patients |
| Q65473288 | Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion |
| Q63403319 | SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia |
| Q65390578 | SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration |
| Q65470493 | Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD |
| Q65380210 | Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON) |
| Q63818224 | Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) |
| Q61955850 | Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy |
| Q63815492 | Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy |
| Q67134263 | Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration |
| Q65386170 | Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration. |
| Q64395094 | Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration |
| Q64397324 | Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration |
| Q64172839 | Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema |
| Q64172886 | Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion |
| Q63319604 | Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration |
| Q65346690 | Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration |
| Q63829742 | Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration |
| Q64673689 | Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone |
| Q64352363 | Safety and Efficacy of Ranibizumab for Diabetic Macular Edema |
| Q64655190 | Safety and Efficacy of Ranibizumab in Diabetic Macular Edema |
| Q65538028 | Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement |
| Q65538024 | Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration |
| Q67133300 | Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD |
| Q66401052 | Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD |
| Q64714960 | Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD) |
| Q61979094 | Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD) |
| Q64352002 | Safety and Tolerability of Ranibizumab in Mono/Bilateral w-AMD Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye |
| Q61980029 | Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration |
| Q63833875 | Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME) |
| Q65383209 | Scotoma Reduction in AMD Patients Treated With Ranibizumab |
| Q65384866 | Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself |
| Q63818194 | Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy |
| Q66046367 | Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab |
| Q63818025 | Seven Year Update of Macular Degeneration Patients |
| Q65350590 | Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME) |
| Q64603371 | Stereotactic Radiotherapy for Wet AMD (STAR) |
| Q64792580 | Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification |
| Q66070857 | Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects |
| Q65471759 | Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema |
| Q61921143 | Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV |
| Q61956683 | Study EvAluating Genotypes While Using Lucentis 2 |
| Q65383011 | Study Evaluating Genotypes Using Lucentis |
| Q65348995 | Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration |
| Q65330703 | Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD |
| Q65377719 | Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration |
| Q65386173 | Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration |
| Q63817092 | Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) |
| Q65335492 | Study of DS-7080a for the Treatment of Macular Degeneration |
| Q64718702 | Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration |
| Q65348632 | Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema |
| Q113891998 | Study of RO7250284 in Participants With Neovascular Age-Related Macular Degeneration |
| Q65537289 | Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration |
| Q67129639 | Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion |
| Q61920596 | Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD |
| Q64680791 | Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids |
| Q63813399 | Study of the Efficacy and Safety of the Ranibizumab Port Delivery System (RPDS) for Sustained Delivery of Ranibizumab in Participants With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) (LADDER) |
| Q64604211 | Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. |
| Q113923960 | Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation |
| Q65359848 | Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration |
| Q63321418 | Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA) |
| Q113909717 | Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD |
| Q66075017 | Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD) |
| Q64376517 | Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®) |
| Q63813226 | Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma |
| Q64643958 | Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration |
| Q66078127 | Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety |
| Q66064500 | Sub-macular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema |
| Q63819093 | Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab |
| Q65380631 | Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD) |
| Q66041872 | Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO |
| Q67134672 | Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF |
| Q64606628 | Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema |
| Q65351792 | Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration |
| Q64395652 | The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates |
| Q64651234 | The Effect of Ranibizumab on Eye Lens Opacity in Cases With Age-Related Macular Degeneration |
| Q64041102 | The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion |
| Q61914904 | The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD) |
| Q64679148 | The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration |
| Q63315901 | The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema |
| Q64723939 | The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study |
| Q65472883 | The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study |
| Q64336837 | The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema |
| Q74279997 | This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab (PDS) in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab |
| Q63404354 | Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD |
| Q65365678 | To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema |
| Q65346721 | To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema |
| Q64801895 | To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus |
| Q64677860 | Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab |
| Q65370649 | Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab |
| Q64697197 | Treatment Of Radiation Retinopathy Trial |
| Q63599699 | Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser |
| Q64642521 | Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis) |
| Q67126517 | Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab |
| Q63340481 | Treatment of Epiretinal Membranes With Ranibizumab |
| Q65470875 | Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy |
| Q65469699 | Treatment of Failing Blebs With Ranibizumab |
| Q65473914 | Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration |
| Q63837541 | Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy |
| Q64351864 | UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) |
| Q74272730 | Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion |
| Q65370178 | Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage |
| Q64720611 | Use of Ranibizumab With Mitomycin C During Trabeculectomy |
| Q61938936 | Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery |
| Q64683959 | Use of Spectral OCT in Combination Therapy |
| Q66044706 | VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP |
| Q64718441 | VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD) |
| Q63340944 | Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy |
| Q61915247 | Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) |
| Q61979344 | Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD) |
| Q65383959 | Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) |
| Q65365680 | Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) |
| Q66064827 | Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibizumab |
| Q64662448 | WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination |
| Q61966807 | Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing |
| Q64644909 | Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept |
| Q66346291 | Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion |
| Q64807426 | ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) |
| Q64803286 | Ziv-aflibercept Efficacy in Better Regulating AMD |
| Q62492946 | A Novel Machine Learning Algorithm to Automatically Predict Visual Outcomes in Intravitreal Ranibizumab-Treated Patients with Diabetic Macular Edema |
| Q64101207 | A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand |
| Q64111269 | Association of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjects |
| Q64045806 | Clinical Efficacy and Safety of Current Interventions for Choroidal Neovascularization Associated with Rare Diseases: A Systematic Literature Review |
| Q59126137 | Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis |
| Q61814808 | Clinical efficacy evaluation of treatment of different degrees of retinal vein occlusion with ranibizumab combined with an argon ion laser |
| Q37672460 | Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma. |
| Q64257305 | Dexamethasone Implant in Patients with Diabetic Macular Edema Resistant to Anti-VEGF Therapy |
| Q64226430 | Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better |
| Q64040777 | Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK |
| Q107169667 | Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications |
| Q61811510 | Pharmacokinetic Simulations of Intravitreal Biologicals: Aspects of Drug Delivery to the Posterior and Anterior Segments |
| Q64220606 | Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO |
| Q61975528 | Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT |
| Q35238074 | Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment |
| Q96225214 | Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema |
| Q39292954 | Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges |
| Q61979152 | Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE) |
| Q61980060 | Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial) |
| Q77319795 | Resolution of diabetic papillopathy after a single intravitreal injection of ranibizumab |
| Q64060594 | Role of inflammatory factors in the effects of aflibercept or ranibizumab treatment for alleviating wet age-associated macular degeneration |
| Q64067383 | Short-term Efficacy and Safety of Ranibizumab for Neovascular Age-related Macular Degeneration in the Real World: A Post-marketing Surveillance Study |
| Q38902223 | The Efficacy and Safety of Current Treatments in Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis |
| Q64113659 | Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study |
| Q64233539 | Two-Year Outcome of Aflibercept for the Treatment of Choroidal Neovascularization in Punctate Inner Choroidopathy |
| Q38843218 | Wet age related macular degeneration management and follow-up |
| Q64096587 | Xy31Prefilled syringes for intravitreal drug delivery |
| Q29006144 | Lucentis | has active ingredient | P3781 |
| Arabic (ar / Q13955) | رانيبيزوماب | wikipedia |
| Ranibizumab | wikipedia | |
| Ranibizumab | wikipedia | |
| Ranibizumab | wikipedia | |
| רניביזומאב | wikipedia | |
| Ranibizumab | wikipedia | |
| ラニビズマブ | wikipedia | |
| or | ରାନିବିଜୁମାବ | wikipedia |
| Ranibizumab | wikipedia | |
| Ranibizumabe | wikipedia | |
| Ранибизумаб | wikipedia | |
| Serbo-Croatian (sh / Q9301) | Ranibizumab | wikipedia |
| Ranibizumab | wikipedia | |
| Ранібізумаб | wikipedia | |
| 兰尼单抗 | wikipedia |
Search more.